Beckman Coulter Life Sciences Acquires Microbioreactor Manufacturer m2p-labs
(Indianapolis, Indiana - November 12, 2020) - Beckman Coulter Life Sciences signed a definitive agreement to acquire m2p-labs, a privately held, microbioreactor manufacturer based in Baesweiler, Germany. m2p-labs is best known for its transformative BioLector plate-based microbioreactors, which support automated solutions for screening and bioprocess development.
“Innovation defines our future,” said Greg Milosevich, President, Beckman Coulter Life Sciences. “m2p-labs core product line complements our existing cell health, liquid handling and laboratory automation business. Our collective team has the opportunity to enhance time-saving solutions for cell line development and process development workflows.”
“m2p-labs and Beckman Coulter Life Sciences share a common vision of accelerating answers, enabling the faster discovery and development of life-changing advances in medicine,” said, Matthias Eggers, Managing Director, m2p-labs. “We are excited to join, and expand, a powerful team to provide invaluable resources to biologics customers around the world.”
m2p-labs was supported in several financings rounds by FIDURA Private Equity Funds and High-Tech Gründerfonds. “It was a privilege for us to work with management on growing m2p-labs to a leading microbioreactor vendor with global reach,” said Klaus Ragotzky, Managing Director and Chairman of the Advisory Board, FIDURA.
m2p-labs associates and products will transition into Beckman Coulter Life Sciences’ Biotechnology Business Unit. The company’s existing Baesweiler, Germany site will remain operational.
About m2p labs GmbH
Based in Baesweiler, Germany (near Aachen), the company was founded in November 2005 as a spin-off of RWTH Aachen University. The company name was derived from the explanation "from microreactor to process" what the m2p-labs systems are used for in laboratories. The company focuses on microreaction and automated solutions for screening and bioprocess development. Our commercialized products are the BioLector, the BioLector Pro, and the FlowerPlate, which provide an intelligent micro fermentation platform. This proprietary technology empowers the biotechnology, chemical, and pharmaceutical industries to increase the number and the information content of microbial experiments (aerobic, microaerophilic, and strictly anaerobic). It enables customers to conduct experiments with high efficiency and excellent quality in microscale at low costs.